Navigation Links
Pacira Pharmaceuticals, Inc. Announces Timing for First Quarter 2011 Financial Results Webcast and Conference Call
Date:5/4/2011

PARSIPPANY, N.J., May 4, 2011 /PRNewswire/ -- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX), an emerging specialty pharmaceutical company, today announced that financial results for the company's first quarter ended March 31, 2011 will be released before the market opens on Wednesday, May 11, 2011. The Pacira management team will host a conference call to discuss the company's financial results and recent and upcoming developments on Wednesday, May 11, 2011 at 10 a.m. EDT. The call can be accessed by dialing 1-866-783-2143 (domestic) or 1-857-350-1602 (international) and providing the passcode 55610905. A replay of the call will be available approximately two hours after the completion of the call and can be accessed by dialing 1-888-286-8010 (domestic) or 1-617-801-6888 (international), and providing the passcode 69231212. The replay will be available for two weeks from the date of the live call.

The live, listen-only webcast of the conference call can be accessed by visiting the investors section of the company's website at www.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the call.

About Pacira

Pacira Pharmaceuticals, Inc. is an emerging specialty pharmaceutical company focused on the development, manufacture and commercialization of novel pharmaceutical products, based on its proprietary DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. In December 2010, Pacira announced that its New Drug Application (NDA) for EXPAREL, the company's most advanced investigational product candidate, had been accepted for filing by the U.S. Food and Drug Administration (FDA). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of July 28, 2011 for the review of the EXPAREL NDA. EXPAREL is a bupivacaine-based product and has completed extensive Phase 3 clinical development for postoperative analgesia by infiltration. EXPAREL consists of bupivacaine encapsulated in DepoFoam, which is designed to address the limitations of widely used medications by enhancing their dosing and/or administration profile. Additional information about Pacira is available at www.pacira.com.

Contacts:

James S. Scibetta
Chief Financial Officer
Pacira Pharmaceuticals, Inc.
(973) 254-3570

Jennifer Beugelmans
Vice President, Investor Relations
Pure Communications, Inc.
(646) 596-7473


'/>"/>
SOURCE Pacira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pacira Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
2. Pacira Pharmaceuticals Reports Fourth Quarter and 2010 Financial Results
3. Pacira Pharmaceuticals to Present at the Barclays Capital 2011 Global Healthcare Conference
4. Pacira Pharmaceuticals EXPAREL™ Data to be Featured at 2011 ASCPT 112th Annual Meeting
5. Pacira Pharmaceuticals Highlights Additional Safety Data on EXPAREL™ for Postsurgical Pain Relief at 2011 American Academy of Orthopaedic Surgeons Annual Meeting
6. Pacira Pharmaceuticals, Inc. Announces Pricing of Its Initial Public Offering
7. Pacira Pharmaceuticals Presents New Data from EXPAREL Phase 3 Study at Orthopaedic Research Societys 57th Annual Meeting
8. Pacira Pharmaceuticals Announces FDA Acceptance of EXPAREL™ New Drug Application for Pain Management
9. Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment
10. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Hernia Repair Presented at the Postgraduate Assembly in Anesthesiology (PGA)
11. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... March 24, 2017  Zymo Research Corp., ... Hamilton Robotics, Inc., who designs, manufactures and ... collaboration that teams Zymo Research,s DNA methylation ... DNA extraction products with Hamilton,s high-throughput automation ... methods for microbiomics and RNA isolation for ...
(Date:3/24/2017)... 24, 2017 Research and Markets has announced the ... report to their offering. ... This report analyzes the worldwide markets for Dental Implants in US$ Million. ... , Japan , Europe , ... Rest of World. Annual estimates and forecasts are provided ...
(Date:3/24/2017)... 24, 2017 FinancialBuzz.com News Commentary  ... According to ... cannabis market research, the legal cannabis market is projected to ... despite conflicting signals from the current presidential administration. The report ... two biggest drivers of growth in this industry are the ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... Vighter established its NAEMT Authorized ... providing Prehospital Trauma Life Support (PHTLS) course scholarships to four medics assigned to ... developed in cooperation with the American College of Surgeons to promote critical thinking ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... world countries to hospitals in the United States, it’s a threat that is ... current obstacles facing infection prevention and offers strategies for the healthcare community to ...
(Date:3/24/2017)... Farifax, VA (PRWEB) , ... March 24, 2017 , ... ... its 2017 Quest Awards . The annual awards, now in their 12th year, ... marketing peers selects the winners. , In 2016, the awards were retooled to recognize ...
(Date:3/24/2017)... ... , ... Texas Physical Therapy Specialists (TexPTS) is pleased to announce the ... clinic is the group’s 7th location in San Antonio and 23rd in Texas. ... care from the clinic, which opened March 22, 2017. , The team ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... related services to families and business owners across eastern Michigan, is connecting with ... families struggling with financial difficulties. , The Oxford/Orion FISH Food Pantry works to ...
Breaking Medicine News(10 mins):